Génotypage moléculaire dans les cancers réfractaires de la thyroïde en 2021 : quand, comment, et pourquoi ? Un travail du réseau TUTHYREF

Brose, 2014, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial, Lancet, 384, 319, 10.1016/S0140-6736(14)60421-9 Wells, 2012, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial, J Clin Oncol, 30, 134, 10.1200/JCO.2011.35.5040 Cancer Genome Atlas Research Network, 2014, Integrated genomic characterization of papillary thyroid carcinoma, Cell, 159, 676, 10.1016/j.cell.2014.09.050 Sykorova, 2015, Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing, Anticancer Res, 35, 2029 Xu, 2016, Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma, Endocr Pathol, 27, 205, 10.1007/s12022-016-9445-4 Tiedje, 2017, NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma, Oncotarget, 8, 42613, 10.18632/oncotarget.17300 Schlumberger, 2015, Lenvatinib in radio-iodine-refractory thyroid cancer, N Engl J Med, 372, 1868, 10.1056/NEJMoa1406470 Duan, 2019, Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing, Histopathology, 75, 890, 10.1111/his.13942 Landa, 2016, Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers, J Clin Invest, 126, 1052, 10.1172/JCI85271 Ibrahimpasic, 2019, Poorly differentiated carcinoma of the thyroid gland: current status and future prospects, Thyroid, 29, 311, 10.1089/thy.2018.0509 Liu, 2016, Associations between BRAF-V600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis, World J Surg Onc, 14, 241, 10.1186/s12957-016-0979-1 Lloyd R, Osamura R, Rosai J, editors. WHO Classification of Tumours of Endocrine Organs. n.d. Fagin, 2016, Biologic and clinical perspectives on thyroid cancer, N Engl J Med, 375, 2307, 10.1056/NEJMra1501993 Yang, 2020, Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis, Endocrine, 67, 44, 10.1007/s12020-019-02117-2 Tahara, 2017, Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid, Eur J Cancer, 75, 213, 10.1016/j.ejca.2017.01.013 Prasad, 2016, NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States, Cancer, 122, 1097, 10.1002/cncr.29887 Ricarte-Filho, 2013, Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers, J Clin Invest, 123, 4935, 10.1172/JCI69766 Nicolson, 2018, Comprehensive genetic analysis of follicular thyroid carcinoma predicts prognosis independent of histology, J Clin Endocrinol Metab, 103, 2640, 10.1210/jc.2018-00277 Gopal, 2018, Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma, Cancer Cell, 34, 242, 10.1016/j.ccell.2018.06.013 Ganly, 2018, Integrated genomic analysis of Hürthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes, Cancer Cell, 34, 256, 10.1016/j.ccell.2018.07.002 Dettmer, 2020, Poorly differentiated thyroid carcinoma: an underdiagnosed entity, Pathology, 41, 1, 10.1007/s00292-019-0600-9 Volante, 2007, Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach, Am J Surg Pathol, 31, 1256, 10.1097/PAS.0b013e3180309e6a Hiltzik, 2006, Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients, Cancer, 106, 1286, 10.1002/cncr.21739 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 Brose, 2016, Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial, Lancet Oncol, 17, 1272, 10.1016/S1470-2045(16)30166-8 Shah, 2017, Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma, JCO, 35, 10.1200/JCO.2017.35.15_suppl.6022 Rothenberg, 2015, Redifferentiation of iodine-refractory BRAF-V600E-mutant metastatic papillary thyroid cancer with dabrafenib, Clin Cancer Res, 21, 1028, 10.1158/1078-0432.CCR-14-2915 Dunn, 2018, Vemurafenib redifferentiation of BRAF MUtant, RAI-refractory thyroid cancers, J Clin Endocrinol Metab, 104, 1417, 10.1210/jc.2018-01478 Durante, 2007, BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism, J Clin Endocrinol Metab, 92, 2840, 10.1210/jc.2006-2707 Ho, 2013, Selumetinib-enhanced radio-iodine uptake in advanced thyroid cancer, N Engl J Med, 368, 623, 10.1056/NEJMoa1209288 Leboulleux, 2021, Trial with trametinib and dabrafenib followed by radioactive iodine administration for metastatic radioactive iodine-refractory differentiated thyroid cancer patients with a BRAF-V600E mutation, J Endocr Soc, 5, 10.1210/jendso/bvab048.1789 Hong, 2020, KRASG12C inhibition with sotorasib in advanced solid tumors, N Engl J Med, 383, 1207, 10.1056/NEJMoa1917239 Cabanillas, 2020, 1916P larotrectinib treatment of advanced TRK fusion thyroid cancer, Ann Oncol, 31, S1086, 10.1016/j.annonc.2020.08.1404 Doebele, 2020, Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials, Lancet Oncol, 21, 271, 10.1016/S1470-2045(19)30691-6 Groussin, 2020, Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer, N Engl J Med, 383, 1686, 10.1056/NEJMc2023094 Seoane, 2018, The right compound for the right target: tackling RET, Ann Oncol, 29, 1623, 10.1093/annonc/mdy188 Subbiah, 2020, State-of-the-art strategies for targeting RET-dependent cancers, JCO, 38, 1209, 10.1200/JCO.19.02551 Wirth, 2020, Efficacy of selpercatinib in RET-altered thyroid cancers, N Engl J Med, 383, 825, 10.1056/NEJMoa2005651 Subbiah, 2020, Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors, JCO, 38, 10.1200/JCO.2020.38.15_suppl.109 Wells, 2015, Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma, Thyroid, 25, 567, 10.1089/thy.2014.0335 Elisei, 2013, Cabozantinib in progressive medullary thyroid cancer, J Clin Oncol, 31, 3639, 10.1200/JCO.2012.48.4659 Ciampi, 2019, Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing, IScience, 20, 324, 10.1016/j.isci.2019.09.030 Accardo, 2017, Genetics of medullary thyroid cancer: an overview, Int J Surg, 41, S2, 10.1016/j.ijsu.2017.02.064 Elisei, 2008, Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study, J Clin Endocrinol Metab, 93, 682, 10.1210/jc.2007-1714 Vuong, 2018, Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis, Endocr Relat Cancer, 25, 633, 10.1530/ERC-18-0056 Subbiah, 2018, Selective RET kinase inhibition for patients with RET-altered cancers, Ann Oncol, 29, 1869, 10.1093/annonc/mdy137 Boichard, 2012, Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon, J Clin Endocrinol Metab, 97, E2031, 10.1210/jc.2012-2092 Moura, 2015, RAS proto-oncogene in medullary thyroid carcinoma, Endocr Relat Cancer, 22, R235, 10.1530/ERC-15-0070 Brown, 2020, RAS-mutated sporadic medullary thyroid cancer: a single-center experience, JCO, 38, 10.1200/JCO.2020.38.15_suppl.6584 Lee, 2020, A phase II trial of tipifarnib for patients with previously treated, metastatic urothelial carcinoma harboring HRAS mutations, Clin Cancer Res, 26, 5113, 10.1158/1078-0432.CCR-20-1246 Ji, 2015, Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer, PLoS Genet, 11, e1005467, 10.1371/journal.pgen.1005467 Grubbs, 2015, RET fusion as a novel driver of medullary thyroid carcinoma, J Clin Endocrinol Metab, 100, 788, 10.1210/jc.2014-4153 Smith, 2016, Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression, Hum Mol Genet, 25, 1836, 10.1093/hmg/ddw057 Grubbs, 2016, Role of CDKN2C copy number in sporadic medullary thyroid carcinoma, Thyroid, 26, 1553, 10.1089/thy.2016.0224 Tamburrino, 2012, Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases, Clin Cancer Res, 18, 3532, 10.1158/1078-0432.CCR-11-2700 Fussey, 2019, The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: a systematic review, Clin Endocrinol, 91, 697, 10.1111/cen.14060 Filetti, 2019, Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†, Ann Oncol, 30, 1856, 10.1093/annonc/mdz400 Hu, 2020, 1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC), Ann Oncol, 31, S1084, 10.1016/j.annonc.2020.08.1401 Hundahl, 1998, A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments], Cancer, 83, 2638, 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1 De Crevoisier, 2004, Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy, Int J Radiat Oncol Biol Phys, 60, 1137, 10.1016/j.ijrobp.2004.05.032 Derbel, 2011, Results of combined treatment of anaplastic thyroid carcinoma (ATC), BMC Cancer, 11, 469, 10.1186/1471-2407-11-469 Maniakas, 2020, Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000–2019, JAMA Oncol, 6, 1397, 10.1001/jamaoncol.2020.3362 Prasongsook, 2017, Survival in response to multimodal therapy in anaplastic thyroid cancer, J Clin Endocrinol Metab, 102, 4506, 10.1210/jc.2017-01180 Bible, 2021, 2021 American Thyroid Association Guidelines for management of patients with anaplastic thyroid cancer: American Thyroid Association Anaplastic Thyroid Cancer Guidelines task force, Thyroid, 31, 337, 10.1089/thy.2020.0944 Kelly, 2014, Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer, Proc Natl Acad Sci USA, 111, 4233, 10.1073/pnas.1321937111 Pérot, 2014, Identification of a recurrent STRN/ALK fusion in thyroid carcinomas, PLoS ONE, 9, e87170, 10.1371/journal.pone.0087170 Bonhomme, 2017, Molecular pathology of anaplastic thyroid carcinomas: a retrospective study of 144 cases, Thyroid, 27, 682, 10.1089/thy.2016.0254 Dias-Santagata, 2020, Response to RET-specific therapy in RET fusion-positive anaplastic thyroid carcinoma, Thyroid, 10.1089/thy.2019.0477 Kunstman, 2015, Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing, Hum Mol Genet, 24, 2318, 10.1093/hmg/ddu749 Pozdeyev, 2018, Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers, Clin Cancer Res, 24, 3059, 10.1158/1078-0432.CCR-18-0373 Pozdeyev, 2020, Molecular therapeutics for anaplastic thyroid cancer, Semin Cancer Biol, 61, 23, 10.1016/j.semcancer.2020.01.005 Molinaro, 2017, Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies, Nat Rev Endocrinol, 13, 644, 10.1038/nrendo.2017.76 Chen, 2018, Molecular profile of advanced thyroid carcinomas by next-generation sequencing: characterizing tumors beyond diagnosis for targeted therapy, Mol Cancer Ther, 17, 1575, 10.1158/1535-7163.MCT-17-0871 Godbert, 2015, Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma, J Clin Oncol, 33, e84, 10.1200/JCO.2013.49.6596 Leroy, 2020, Remarkable response to ceritinib and brigatinib in an anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma previously treated with crizotinib, Thyroid, 30, 343, 10.1089/thy.2019.0202 Kohno, 2020, REToma: a cancer subtype with a shared driver oncogene, Carcinogenesis, 41, 123, 10.1093/carcin/bgz184 Subbiah, 2017, Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer, JCO, 36, 7, 10.1200/JCO.2017.73.6785 Keam, 2018, 1821PD updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF-V600E–mutated anaplastic thyroid cancer (ATC), Ann Oncol, 29 Cabanillas, 2018, Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma, Thyroid, 28, 945, 10.1089/thy.2018.0060 Hong, 2020, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Lancet Oncol, 21, 531, 10.1016/S1470-2045(19)30856-3 Giannini, 2019, Immune profiling of thyroid carcinomas suggests the existence of two major phenotypes: an ATC-like and a PDTC-like, J Clin Endocrinol Metab, 104, 3557 Angell, 2014, BRAF-V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration, Thyroid, 24, 1385, 10.1089/thy.2014.0134 Capdevila, 2020, PD-1 blockade in anaplastic thyroid carcinoma, J Clin Oncol, 38, 2620, 10.1200/JCO.19.02727 Lorch, 2020, A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC), JCO, 38, 10.1200/JCO.2020.38.15_suppl.6513 Iyer, 2018, Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma, J Immunother Cancer, 6, 68, 10.1186/s40425-018-0378-y Haugen, 2020, Lenvatinib plus pembrolizumab combination therapy in patients with radio-iodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): results of a multicenter phase II international thyroid oncology group trial, JCO, 38, 10.1200/JCO.2020.38.15_suppl.6512 Dierks, 2020, Ann Oncology, 31, S1085, 10.1016/j.annonc.2020.08.1403 Haugen, 2020, 1917P pembrolizumab salvage add-on therapy in patients with radio-iodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: results of a multicenter phase II International Thyroid Oncology Group Trial, Ann Oncol, 31, S1086, 10.1016/j.annonc.2020.08.1405 Cabanillas, 2020, Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC), JCO, 38, 10.1200/JCO.2020.38.15_suppl.6514 Chintakuntlawar, 2019, A phase 2 Study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer, Thyroid, 29, 1615, 10.1089/thy.2019.0086 Marabelle, 2020, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, Lancet Oncol, 21, 1353, 10.1016/S1470-2045(20)30445-9 Le, 2019, Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164, J Clin Oncol, 38, 11, 10.1200/JCO.19.02107 Sautès-Fridman, 2019, Tertiary lymphoid structures in the era of cancer immunotherapy, Nat Rev Cancer, 19, 307, 10.1038/s41568-019-0144-6 Gibney, 2016, Predictive biomarkers for checkpoint inhibitor-based immunotherapy, Lancet Oncol, 17, e542, 10.1016/S1470-2045(16)30406-5